Adult Macular Degeneration
(AMD)En Español (Spanish Version)More InDepth Information on This Condition
The retina is the tissue that lines the back of the eye. It sends visual signals to the brain. The macula is part of the retina. It is responsible for central vision. Macular degeneration is decline of the macula. It causes a gradual loss of sharp, central vision. The condition is mainly a disease of aging. In rare cases, it can occur in younger people.
Copyright © Nucleus Medical Media, Inc.
There are two types of adult (or age-related) macular degeneration (AMD):
- Dry AMD—This occurs when an area of the retina becomes diseased. This leads to a slow breakdown of cells in the macula. The central vision is gradually lost. Dry AMD accounts for the majority of cases (90%).
- Wet AMD—As dry AMD worsens, new blood vessels may begin to grow. These new blood vessels often leak blood and fluid under the macula. This can lead to permanent damage of the macular region. Wet AMD occurs in only 10% of the people with AMD. It accounts for the majority of blindness from this disease.
Factors that increase your risk for AMD include:
In some people, AMD advances very slowly. It has little effect on their vision. In others, the disease progresses faster. It may lead to significant vision loss. Both dry and wet AMD cause no pain.
- Blurred vision
- Difficulty seeing details in front of you, such as faces or words in a book
- Blurred vision that goes away in brighter light
- A small, but growing blind spot in the middle of the field of vision
- Straight lines (eg, door frames) appear crooked or distorted
The doctor will ask about your symptoms and medical history. A physical exam will be done. The doctor may suspect AMD if you are older and have had recent changes in your central vision. A specialist will look for signs of the disease. The doctor will use eye drops to dilate (enlarge) your pupils. This will allow a view of the back of the eye.
You may also be asked to view an Amsler grid. This is a pattern that looks like a checkerboard. Changes in your central vision will cause the grid to appear distorted. This is a sign of AMD.
Treatment may include:
Research has shown that certain high-dose vitamins and minerals may slow the progression of the disease in some people.
This procedure is used in some cases of wet AMD. A strong laser light beam is aimed onto the new blood vessels. The beam will destroy the vessels. It usually takes less than 30 minutes to complete. You may need additional laser treatments. This treatment is used less often since the development of newer treatments.
This procedure is a type of treatment that involves injecting a light-sensitive dye into the blood. The affected areas in the back of the eye are then hit with a special laser light. The light activates the dye to destroy certain blood vessels. It also takes less than 30 minutes. You may need to have additional treatments.
Vascular Endothelial Growth Factor Inhibitor
Another way to treat wet AMD is an injection of a special medicine. It is called a vascular endothelial growth factor (VEGF) inhibitor. The medicine is injected into the vitreous (fluid) in the back of the eye. This method is quickly growing in popularity. It usually needs to be repeated multiple times. About 1/3 of patients show significant improvement in vision.
There are no guidelines for preventing AMD. For overall eye health:
- Have regular eye exams. The exam should include dilation to closely look at the retina.
- If you smoke, quit .
- Consider taking a multivitamin with antioxidants every day.
- Consider omega-3 fatty acid supplements.
If you have AMD, your doctor may advise you to monitor for problems by using an Amsler grid at home. Your ophthalmologist should discuss the various treatment options with you.
American Macular Degeneration Foundation
Macular Degeneration Foundation
The National Coalition for Vision Health
Age-related macular degeneration. National Eye Institute website. Available at: http://www.nei.nih.gov/health/maculardegen/index.asp . Accessed July 20, 2009.
Liew G, Mitchell P, Gillies MC, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med . 2006;355:1419-1431.
Macular Degeneration Foundation website. Available at: http://www.eyesight.org . Accessed July 20, 2009.
National Eye Institute website. Available at: http://www.nei.nih.gov/ . Accessed July 20, 2009.
Photodynamic therapy: an emerging treatment for classically leaky neovascularizations. Macular Degeneration Foundation website. Available at: http://www.eyesight.org/Research/Research-Photodynamic/research-photodynamic.html . Accessed July 20, 2009.
11/1/2007 DynaMed's Systematic Literature Surveillance
DynaMed's Systematic Literature Surveillance
: Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration.
Cochrane Database of Systematic Reviews.
Last reviewed September 2011 by Christopher Cheyer, MD
Last updated Updated: 9/1/2011
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2010 EBSCO Publishing All rights reserved.